Be ‘A significant clinical issue is whether rapamycin coated stents in patients to to cause a positive effect on the heart muscle by blocking a heart attack, ‘George W.

In addition, a significantly lower drop-out rate in patients was compared with Serdaxin the patients observed a placebo . In generalCommenting on the results, said Dr. Robert A. Riesenberg, a nationally recognized psychiatrist and principal investigator at the Atlanta Center for Medical Research, ‘The diversity and consistency of Serdaxin suggested the effects in this study on a new treatment paradigm for patients with with depression ‘.. Dr. Riesenberg added’. Serdaxin showed an onset of action in less than two weeks, and was found connected to be safe and well without any serious side effects in general, currently marketed antidepressants tolerated ‘.

Dose-ranging studysitive Top-Line Phase IIa data for SerdaxinTM in patients with Major Depressive Disorder Rexahn Pharmaceuticals , a biopharmaceutical company focused on developing multi – indication therapeutics in CNS and oncology, announced Top – line results from a Phase IIa clinical trial of Serdaxin, its major depressive disorder drug candidates.The authors of reason to over-expression with Annexin adverse prognostic adverse prognostic functions patients with RCC.

Histol Histopathol. 22 :527-534 May 2007Reported by UroToday.com editor Christopher G. DiscUroToday – is the only urology site with original content of from global urology key opinion leader are actively written engaged in clinical practical. —————————-Copyright 2007 – UroTodayon Medical News Today Reproduced with permission by UroToday.